- <![CDATA[Neoadjuvant T-DXd Followed by THP Improves RCB in HER2+ Breast Cancer]]><![CDATA[Treatment with neoadjuvant T-DXd followed by THP resulted in lower RCB vs ddAC-THP in patients with high-risk, HER2-positive early-stage breast cancer.]]>onclive · 2mo ago↗ source
- Amgen, AbbVie say IRA negotiations impacted Q1 salesAt least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in January. Amgen and AbbVie reported in th…Endpoints · 2mo ago↗ source
- <![CDATA[Dr Lee on Research Collaborations Studying PD-L1 as a Biomarker in NSCLC]]><![CDATA[Jonathan Wennan Lee, MD, MSc, discusses future directions for studying PD-L1 as a predictive biomarker in EGFR-mutated NSCLC. ]]>onclive